Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nab-paclitaxel + Toripalimab-tpzi |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | triple-receptor negative breast cancer | predicted - sensitive | Nab-paclitaxel + Toripalimab-tpzi | Phase III | Actionable | In a Phase III trial (TORCHLIGHT), treatment with Loqtorz (toripalimab-tpzi) plus Abraxane (nab-paclitaxel) demonstrated safety and led to an improved median progression-free survival (mPFS) compared to nab-paclitaxel plus placebo in CD274 (PD-L1)-positive (CPS >/= 1) triple-negative breast cancer patients, with a mPFS of 8.4 vs 5.6 mo (HR=0.65, p=0.0102) and in the intention to treat population, a mPFS of 8.4 vs 6.9 mo (PMID: 38191615; NCT03777579, NCT04085276). | 38191615 |
PubMed Id | Reference Title | Details |
---|---|---|
(38191615) | Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. | Full reference... |